Mechanical 'artificial hearts' can remove need for heart transplant by returning heart to normal

Mechanical 'artificial hearts' can be used to return severely failing hearts to their normal function, potentially removing the need for heart transplantation <em> - News Release</em>

Imperial College London News Release

Under strict embargo for
22.00 GMT / 17.00 EST
Wednesday 1 November 2006

Mechanical 'artificial hearts' can be used to return severely failing hearts to their normal function, potentially removing the need for heart transplantation, according to new research.

The mechanical devices, known as Left Ventricular Assist Devices (LVADs), are currently used in patients with very severe heart failure whilst they await transplantation. The new study, published in the New England Journal of Medicine, shows that using an LVAD combined with certain drug therapies can shrink the enlarged heart and enable it to function normally once the LVAD is removed.

For the study, researchers from Imperial College London and the Royal Brompton and Harefield NHS Trust gave the full combination therapy to 15 severely ill patients. Of these 15, 11 recovered. Of these, 88 percent were free from recurrence of heart disease five years later. Their quality of life was measured as being at nearly normal.

Dr Emma Birks , from the Heart Science Centre at Imperial and the Royal Brompton and Harefield NHS Trust, and lead author of the study, said: "Donor heart transplant has for many years been the gold standard in the treatment of those with severe heart failure. It has proven greatly successful but is not without its shortcomings – particularly the shortage of donor hearts and the risk of organ rejection.

"This therapy has the potential to ease the pressure on the waiting list while also offering patients a better alternative to a donor heart – their own, healthy heart," she added.

Professor Sir Magdi Yacoub , from the Heart Science Centre at Imperial and the Royal Brompton and Harefield NHS Trust, said: "We are impressed by the dramatic, sustained improvement in the condition of these severely ill patients and we believe that this is due to the additive effects of the particular combination therapy used. The improvement observed was far greater than what has been reported to date for any other therapy in patients with severe, but less advanced, forms of heart failure.

"The study also highlights the fact that 'end stage' heart failure can be reversed and that the heart has the capacity to regenerate itself. It therefore stimulates the search for other strategies and more therapeutic targets in this expanding field of regenerative therapy," he added.

LVADs are currently mainly used in those patients awaiting heart transplant, whose heart failure is very severe. The researchers are hopeful that the technique used in this study could also be used to restore heart function amongst heart patients who are not awaiting transplants.

LVADs work by being connected to the left ventricle of the heart, either directly or by a tube. They remove oxygen rich blood from the left ventricle and take the blood to a mechanical pump. The mechanical pump then pumps the oxygen rich blood into another tube which is connected to the aorta. Once blood is in the aorta, it can be transported to the rest of the body.

Patients were treated with drugs which encourage reverse remodelling of the heart, prevent atrophy and prevent the heart from shrinking beyond its desirable size. The drugs used were lisinopril, carvedilol, spironolactone and losartan in the first stage of treatment and bisoprolol and clenbuterol in the second.

The next step for the researchers is a larger multi-centre trial named the Harefield Recovery Protocol (HARP) study, which is envisaged to start soon on both sides of the atlantic. The researchers are also continuing their molecular and cellular research and studying the mechanistic and therapeutic targets which have made the recovery observed in this study possible.

The research was funded by Thoratec, the Royal Brompton and Harefield Charitable Trustees, the British Heart Foundation, and the Magdi Yacoub Institute.

-ends-

For further information please contact:

Laura Gallagher
Press Officer
Imperial College London
e-mail: L.Gallagher@imperial.ac.uk
Telephone: +44 (0)207 594 6702 or ext. 46702
Mob: +44 (0)7803 886 248

Notes to editors:

1. "Left Ventricular Assist Device and Drug Therapy for Reversal of Heart Failure" New England Journal of Medicine, 2 November 2006

Emma J Birks(1)(2), Patrick D Tansley(1)(2), James Hardy(1)(2), Robert S George(1)(2), Christopher T Bowles(1)(2), Margaret Burke(1), Nicholas R Banner(1), Asghar Khaghani(1)(2), Magdi H Yacoub(1)(2)*

(1) Royal Brompton and Harefield NHS Trust, Harefield, UK
(2) Heart Science Centre, National Heart and Lung Institute, Imperial College London, UK
* Corresponding author

2. Consistently rated in the top three UK university institutions, Imperial College London is a world leading science-based university whose reputation for excellence in teaching and research attracts students (11,000) and staff (6,000) of the highest international quality. Innovative research at the College explores the interface between science, medicine, engineering and management and delivers practical solutions that enhance the quality of life and the environment - underpinned by a dynamic enterprise culture.
Website: www.imperial.ac.uk